Arvinas (ARVN) Expected to Announce Earnings on Wednesday

Arvinas (NASDAQ:ARVN) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Arvinas to post earnings of ($0.8671) per share and revenue of $16.82 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:00 AM ET.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $2.95. The company had revenue of $249.70 million for the quarter, compared to analyst estimates of $60.71 million. During the same quarter last year, the business earned ($0.84) earnings per share. The company’s revenue was up 1014.7% on a year-over-year basis. On average, analysts expect Arvinas to post $0.05 EPS for the current fiscal year and ($3.37) EPS for the next fiscal year.

Arvinas Stock Performance

Shares of NASDAQ:ARVN opened at $7.45 on Wednesday. Arvinas has a 12-month low of $6.74 and a 12-month high of $14.51. The business has a 50 day moving average of $8.19 and a 200-day moving average of $9.77.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ARVN shares. Wedbush lifted their price target on Arvinas from $11.00 to $12.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. BTIG Research reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Arvinas in a report on Tuesday, August 4th. Zacks Research upgraded Arvinas from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 9th. Wells Fargo & Company reissued an “equal weight” rating and set a $11.00 target price (down from $15.00) on shares of Arvinas in a report on Tuesday, August 4th. Finally, Wall Street Zen raised shares of Arvinas from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.40.

About Arvinas

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.